GLP-1 agonists are being considered as a potential game-changer, but their impact is contingent on accessibility and affordability. Research on these drugs, including semaglutide, suggests various benefits, such as weight loss, improved fatty liver disease, and reduced inflammation, in people with HIV. However, the effectiveness of treatment changes and the relationship between certain medications and weight gain or heart risks are also being explored.